Hold BKNG core position with protective put hedge and staged tactical adds on confirmed technical breakout
The HOLD verdict is the calibrated synthesis because four converging analytical streams—the calibrated research manager/trader consensus, the prior-decision fingerprint lessons, the cross-ticker defensive-compounder reflections, and the neutral analyst's third-option framework—all point to preservation with discipline rather than directional override. The 8/31 reflection explicitly stated that when a quality compounder exhibits deteriorating technicals absent a confirmed catalyst, Hold is the right directional bias but must be paired with the protective-put hedge, because unresolved compression at ATR $6.60 costs roughly 1% alpha per week of drift before the catalyst window resolves. The current setup mirrors the same fingerprint: MACD histogram at -2.69 and widening, price below 10 EMA at $203.97 and VWMA, RSI at 47.67 with bearish divergence against the August 19 bounce, four high-volume distribution sessions in two weeks, ATR elevated at $6.46, but no capitulation flush, no confirmed close <$197.46, Q3 earnings still ~6 weeks out as the binary resolution. The neutral analyst's framework—maintain core, hedge tactically with $195-197 protective put (1-2% of position value, 3-4 week expiry), and add at 10-15% on confirmed breakout—is the calibrated synthesis that honors both directional neutrality and risk discipline.
| Position | Action |
|---|---|
| No fresh capital deployment at current price ($199.60) | Maintain existing core position |
| Confirmed close above $203.97 with above-average volume and RSI >50 | Add 10-15% tactical position (capped, not 25%) |
| Confirmed close above $203.97 with above-average volume and RSI >50 AND post-Q3 earnings beat-and-raise | Add further 5-10% tactical position |
| Confirmed close above $208.50 (Bollinger middle) | Trim 25-30% of tactical gains |
| Confirmed close above $214.40 (prior high) on volume >7M shares coinciding with Q3 deferred-revenue validation OR Fed dovish pivot | Upgrade to Overweight/Buy; scale out remaining tactical at $226 stretch target on confirmed breakout with volume |
| Confirmed close below $197.46 with momentum confirmation | Trim 25-30% of tactical position |
| Decisive break of $192.91 50 SMA on >2× average volume | Trim 50%+ of tactical position |
| Decisive break of $192.91 on >2× average volume OR Q3 print at low end of guidance with second consecutive guide-down | De-risk to Underweight |
| Price decline toward $197.46 or lower | Do not average down |
BKNG is a high-quality compounder priced like a cyclical laggard at 16x forward P/E with 0.72 PEG, 37% EPS growth, and a fresh Rosenblatt initiation, making the current technical pullback to the 50 SMA a "coiled spring" entry point rather than a structural breakdown.
| Indicator | Value | Signal |
|---|---|---|
| 200 SMA | 185.33 | bullish |
| 50 SMA | 192.91 | bullish |
| 10 EMA | 203.97 | bearish |
| RSI(14) | 47.67 | neutral |
| MACD Line | 2.34 | bearish |
| MACD Signal | 5.03 | bearish |
| MACD Histogram | -2.69 | bearish |
| Bollinger Upper Band | 219.62 | neutral |
| Bollinger Middle Band | 208.54 | neutral |
| Bollinger Lower Band | 197.46 | bearish |
| ATR(14) |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Rosenblatt Securities initiated coverage on Aug 31 naming BKNG the 'Best-Positioned Online Travel Agency' in the sector, providing a structural multi-year framework for re-rating BKNG upward.
EV: +3–4% (bull's recalculation vs bear's +1.3%) · concedes: Tactically the chart is choppy; There is a no-man's-land between $197 and $204; Close below $197.46 opens move to 50 SMA at $192.91, then 200 SMA at $185.33 (~7% downside); Q3 earnings bar is high for disappointment
BKNG at $199.60 is a value trap: great fundamentals are already priced in while technical momentum is decisively bearish, sector leadership is rotating away, and the valuation premium to a ZIRP-era multiple doesn't hold in a restrictive rate environment.
· concedes: BKNG is a high-quality compounder with elite margins and dominant market position; Capital return yield of 5.1% is roughly in line with S&P average (not exceptional but real); Forward P/E of 16x is technically below the 5-year average of 18-22x; The buyback program does return capital and mechanically supports EPS
→ vs conservative: Waiting based on price below 10 EMA by four dollars on a stock with this quality profile (9B FCF, 0.72 PEG, 34% margins) is performance anxiety, not risk management
→ vs conservative: Stop at 192.91 implies only 3.5% downside risk against 7%+ upside to prior high—better than 2:1 risk-reward being missed by conservative framework
→ vs conservative: Bear case anchoring on YTD -6.66% ignores 17.3% six-month rally beating S&P by 550bps—this is recovery in motion, not a laggard
→ vs conservative: Value trap narrative contradicted by 450bps margin expansion, 47% FCF growth, 18.5% share reduction, and 37% forward EPS growth
→ vs conservative: 200 SMA still rising and 50 SMA in uptrend—long-term and medium-term structures remain bullish despite short-term MACD bearish cross
→ vs neutral: Chop zone framing is the most dangerous mindset—chop zones are where fortunes are made by those with conviction to act
→ vs neutral: Every major catalyst positioned to surprise upside (Rosenblatt initiation fresh, Q3 earnings mid-Q4, recession odds collapsing at 8%), not downside
→ vs neutral: Sitting flat systematically fades positive expected value—HOLD with staged adds preserves capital for catalyst while maintaining exposure
→ vs neutral: HOLD with breakout adds is strategic aggression, not timidity—25% incremental cap is loading missiles before mission, not aborting it
→ vs conservative: Anyone anchoring on four-dollar gap below 10 EMA will become exit liquidity when this rips on 16x forward earnings and 0.72 PEG re-rating
| 6.46 |
| neutral |
Support: 197.46 · 192.91 · 185.33 | Resistance: 203.97 · 208.54 · 214.42 · 219.62
BKNG exhibits a mixed technical setup with 2 bullish signals (long-term 200 SMA and medium-term 50 SMA both rising) offset by 5 bearish/neutral-leaning indicators including bearish 10 EMA breakdown, bearish MACD crossover with widening negative histogram (-2.69), and RSI bearish divergence from the Aug 7 peak (73.15 vs 65.23 on Aug 19). The critical inflection sits at the lower Bollinger Band ($197.46), with price currently only $2.14 above this level. A close below triggers downside toward 50 SMA at $192.91 (~7% total downside), while reclaiming the 10 EMA ($203.97) would be required to neutralize the short-term bearish setup. Volume analysis shows distribution-style selling (Aug 17, 27, 31, Sep 1 all high-volume red days), contrasting with the high-conviction buy climax on Aug 28 (9.07M shares).
Market Cap
~$150.0 B
TTM P/E
22.18
Forward P/E
16.13
PEG Ratio
0.72
Price / Book
-14.03
EPS (TTM)
$9.00
Forward EPS
$12.38
EPS Growth Expected
+37%
Dividend Yield
0.86%
Beta
1.07
52-Week High
$226.10
52-Week Low
$150.14
50-Day MA
$193.03
200-Day MA
$185.88
Revenue 2021
$11.00 B
Revenue 2022
$17.09 B
Revenue 2023
$21.37 B
Revenue 2024
$23.74 B
Revenue 2025
$26.92 B
Revenue TTM
$28.24 B
Operating Margin 2022
29.8%
Operating Margin 2023
27.3%
Operating Margin 2024
31.8%
Operating Margin 2025
32.8%
Operating Margin TTM
34.4%
Net Margin 2022
17.9%
Net Margin 2023
20.1%
Net Margin 2024
24.8%
Net Margin 2025
20.1%
Net Margin TTM
25.5%
Net Income 2022
$3.06 B
Net Income 2023
$4.29 B
Net Income 2024
$5.88 B
Net Income 2025
$5.40 B
Net Income TTM
$7.21 B
EBITDA 2022
$4.92 B
EBITDA 2023
$7.04 B
EBITDA 2024
$9.34 B
EBITDA 2025
$9.22 B
EBITDA TTM
$10.41 B
ROA
20.4%
Gross Profit 2022
~$14.5 B
Gross Profit 2023
~$18.4 B
Gross Profit 2024
~$20.7 B
Gross Profit 2025
~$23.5 B
Gross Profit TTM
~$24.6 B
Operating Income 2022
$5.10 B
Operating Income 2023
$5.84 B
Operating Income 2024
$7.56 B
Operating Income 2025
$8.83 B
Sales & Marketing 2025
$11.64 B
G&A 2025
$4.26 B
Salaries & Wages 2025
$3.40 B
D&A 2025
$623 M
Total Operating Expenses 2025
$17.64 B
Total Assets
$29.26 B
Cash & ST Investments
$17.20 B
Total Debt
$19.29 B
Net Debt
$1.53 B
Working Capital
$5.57 B
Current Ratio
1.09
Stockholders' Equity
-$5.58 B
Treasury Stock
$54.32 B
Retained Earnings
$40.67 B
Deferred Revenue
$5.27 B
OCF 2022
$6.55 B
OCF 2023
$7.34 B
OCF 2024
$8.32 B
OCF 2025
$9.41 B
CapEx 2022
$0.37 B
CapEx 2023
$0.35 B
CapEx 2024
$0.43 B
CapEx 2025
$0.32 B
FCF 2022
$6.19 B
FCF 2023
$7.00 B
FCF 2024
$7.89 B
FCF 2025
$9.09 B
Share Repurchases 2022
$6.62 B
Share Repurchases 2023
$10.38 B
Share Repurchases 2024
$6.51 B
Share Repurchases 2025
$6.44 B
Dividends 2024
$1.17 B
Dividends 2025
$1.25 B
Shares Outstanding 2022
1,001 M
Shares Outstanding 2023
913 M
Shares Outstanding 2024
852 M
Shares Outstanding 2025
816 M
Diluted EPS 2022
$3.05
Diluted EPS 2023
$4.70
Diluted EPS 2024
$6.91
Diluted EPS 2025
$6.62
Diluted EPS TTM
$9.00
Strengths
Concerns
BUY
Macro: Fed policy: 89% probability of no rate cuts in 2026 (hawkish hold / restrictive-for-longer). US recession by end-2026: 8% (declining -1.0pp). UK recession 2026: 8% (-3.5pp); Japan: 7% (-15.0pp). Risk-on tone prevailing with global equities reclaiming ground; gold/silver bid coexists with equity strength (late-cycle goldilocks). No FRED macro data available (API not configured).